|
|
Article: Micrologix receives FDA fast track designation for MBI 226.
- Article from:
- PR Newswire
- Article date:
- September 8, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Trading Symbol
MBI (TSE/VSE)
MGIXF (US over the counter)
VANCOUVER, Sept. 7 /CNW-PRN/ - Micrologix Biotech Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted fast track designation to MBI 226, the Company's antimicrobial drug product for the prevention of central venous catheter-related bloodstream infections.
The fast track process was authorized by the FDA Modernization Act of 1997. It is designed to facilitate the development and expedite the review of new drugs or biologicals that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet ...